Normal clinical outcome in untreated subjects with mild hyperphenylalaninemia
- PMID: 11264437
- DOI: 10.1203/00006450-200104000-00015
Normal clinical outcome in untreated subjects with mild hyperphenylalaninemia
Abstract
ABSTRACT There is international consensus that patients with phenylalanine (Phe) levels <360 microM on a free diet do not need Phe-lowering dietary treatment whereas patients with levels >600 microM do. Clinical outcome of patients showing Phe levels between 360 and 600 microM in serum on a free nutrition has so far only been assessed in a small number of cases. Therefore, different recommendations exist for patients with mild hyperphenylalaninemia. We investigated in a nationwide study 31 adolescent and adult patients who persistently displayed serum Phe levels between 360 and 600 microM on a normal nutrition with a corresponding genotype. Because of limited accuracy of measurements, Phe levels should be looked on as an approximation, but not as an absolute limit in every instance. In addition to serum Phe levels, the assessment program consisted of comprehensive psychological testing, magnetic resonance imaging of the head, (1)H magnetic resonance spectroscopy, and genotyping. We found a normal intellectual (intelligence quotient, 103 +/- 15; range, 79-138) and educational (school performance and job career) outcome in these subjects as compared with healthy control subjects (intelligence quotient, 104 +/- 11; range, 80-135). Magnetic resonance imaging revealed no changes of cerebral white matter in any patient, and (1)H magnetic resonance spectroscopy revealed brain Phe levels below the limit of detection (<200 microM). In the absence of any demonstrable effect, dietary treatment is unlikely to be of value in patients with mild hyperphenylalaninemia and serum Phe levels <600 microM on a free nutrition, and should no longer be recommended. Because of a possible late-onset phenylketonuria, Phe levels of untreated patients should be monitored carefully at least during the first year of life. Nevertheless, problems of maternal phenylketonuria should still be taken into account.
Similar articles
-
Intellectual, neurologic, and neuropsychologic outcome in untreated subjects with nonphenylketonuria hyperphenylalaninemia. German Collaborative Study on Phenylketonuria.Pediatr Res. 1997 Sep;42(3):378-84. doi: 10.1203/00006450-199709000-00020. Pediatr Res. 1997. PMID: 9284280
-
Impact of the phenylalanine hydroxylase gene on maternal phenylketonuria outcome.Pediatrics. 2003 Dec;112(6 Pt 2):1530-3. Pediatrics. 2003. PMID: 14654659
-
Variability of blood-brain ratios of phenylalanine in typical patients with phenylketonuria.J Cereb Blood Flow Metab. 2001 Mar;21(3):276-84. doi: 10.1097/00004647-200103000-00011. J Cereb Blood Flow Metab. 2001. PMID: 11295882 Clinical Trial.
-
Neurocognitive functioning in adults with phenylketonuria: results of a long term study.Mol Genet Metab. 2013;110 Suppl:S44-8. doi: 10.1016/j.ymgme.2013.08.013. Epub 2013 Aug 31. Mol Genet Metab. 2013. PMID: 24071437
-
In-vivo NMR spectroscopy in patients with phenylketonuria: changes of cerebral phenylalanine levels under dietary treatment.Neuropediatrics. 1995 Aug;26(4):199-202. doi: 10.1055/s-2007-979753. Neuropediatrics. 1995. PMID: 8544958
Cited by
-
Executive functions in preschool children with moderate hyperphenylalaninemia and phenylketonuria: a prospective study.Orphanet J Rare Dis. 2023 Jul 3;18(1):175. doi: 10.1186/s13023-023-02764-9. Orphanet J Rare Dis. 2023. PMID: 37400895 Free PMC article.
-
Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial.Orphanet J Rare Dis. 2017 Mar 9;12(1):47. doi: 10.1186/s13023-017-0600-x. Orphanet J Rare Dis. 2017. PMID: 28274234 Free PMC article. Clinical Trial.
-
Adult cognitive outcomes in phenylketonuria: explaining causes of variability beyond average Phe levels.Orphanet J Rare Dis. 2019 Nov 28;14(1):273. doi: 10.1186/s13023-019-1225-z. Orphanet J Rare Dis. 2019. PMID: 31779649 Free PMC article.
-
Body composition profile of young patients with phenylketonuria and mild hyperphenylalaninemia.Int J Endocrinol Metab. 2014 Jul 1;12(3):e16061. doi: 10.5812/ijem.16061. eCollection 2014 Jul. Int J Endocrinol Metab. 2014. PMID: 25237320 Free PMC article.
-
Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial.Orphanet J Rare Dis. 2021 Aug 3;16(1):341. doi: 10.1186/s13023-021-01968-1. Orphanet J Rare Dis. 2021. PMID: 34344399 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical